Secondary metabolites of Alternaria alternate appraisal of their SARS-CoV-2 inhibitory and anti-inflammatory potentials
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0313616 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Fatma A Moharram und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacognosy, Faculty of Pharmacy, Helwan University, Cairo, Egypt. Hauptthemen laut MEDLINE: SARS-CoV-2, Anti-Inflammatory Agents, Alternaria, Antiviral Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council of Taiwan, China Medical University Hospital.
Abstract (Originalsprache)
This study identifies the secondary metabolites from Alternaria alternate and evaluates their ACE-2: Spike RBD (SARS-CoV-2) inhibitory activity confirmed via immunoblotting in human lung microvascular endothelial cells. In addition, their in vitro anti-inflammatory potential was assessed using a cell-based assay in LPS-treated RAW 264.7 macrophage cells. Two novel compounds, altenuline ( 1 ), phthalic acid bis (7’/7’’ pentyloxy) isohexyl ester ( 2 ), along with 1-deoxyrubralactone ( 3 ) alternariol-5- O -methyl ether ( 4 ) and alternariol ( 5 ) were identified. Molecular docking and in vitro studies showed that compounds 2 and 4 were promising to counteract SARS-CoV-2 attachment to human ACE-2. Thus, they are considered promising natural anti-viral agents. SwissADME in silico analysis was conducted to predict the drug-like potential. Immunoblotting analysis confirmed that the tested compounds ( 1–4 ) demonstrated downregulation of ACE-2 expression in the endothelial cells from the lungs with variable degrees. Furthermore, the tested compounds ( 1–4 ) showed promising anti-inflammatory activities through TNF-α: TNFR2 inhibitory activity and their inhibitory effect on the proinflammatory cytokines (TNF-α and IL-6) in LPS-stimulated monocytes. In conclusion, our study, for the first time, provides beneficial experimental confirmation for the efficiency of the A . alternate secondary metabolites for the treatment of COVID-19 as they hinder SARS-CoV-2 infection and lower inflammatory responses initiated by SARS-CoV-2. A . alternate and its metabolites are considered in developing preventative and therapeutic tactics for COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacognosy, Faculty of Pharmacy, Helwan University, Cairo, Egypt.
- Biochemistry and Molecular Biology Department, Faculty of Pharmacy, Helwan University, Cairo, Egypt.
- Genetic Engineering and Biotechnology Division, Microbial Chemistry Department, National Research Centre, Giza, Egypt.
- Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Helwan University, Cairo, Egypt.
- School of Chinese Medicine, China Medical University, Taichung, Taiwan.
- Graduate Institute of Pharmacognosy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
ORCID-Profile: Kuei-Hung Lai, Mohamed S Mady
Förderung
- National Science and Technology Council of Taiwan
- China Medical University Hospital
Zitieren
APA
Moharram, F. A., Ibrahim, R. R., Mahgoub, S., Abdel-Aziz, M. S., Said, A. M., Huang, H. C., Chen, L. Y., Lai, K. H., Hashad, N., & Mady, M. S. (2025). Secondary metabolites of Alternaria alternate appraisal of their SARS-CoV-2 inhibitory and anti-inflammatory potentials. PLOS ONE. https://doi.org/10.1371/journal.pone.0313616
Vancouver
Moharram FA, Ibrahim RR, Mahgoub S, Abdel-Aziz MS, Said AM, Huang HC, et al. Secondary metabolites of Alternaria alternate appraisal of their SARS-CoV-2 inhibitory and anti-inflammatory potentials. PLOS ONE. 2025. doi:10.1371/journal.pone.0313616
BibTeX
@article{Moharram2025,
author = {Moharram, Fatma A and Ibrahim, Reham R and Mahgoub, Shahenda and Abdel-Aziz, Mohamed S and Said, Ahmed M and Huang, Hui-Chi and Chen, Lo-Yun and Lai, Kuei-Hung and Hashad, Nashwa and Mady, Mohamed S},
title = {Secondary metabolites of Alternaria alternate appraisal of their SARS-CoV-2 inhibitory and anti-inflammatory potentials},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0313616}
}
EUVIMED